ST Elevated Myocardial Infarction Undergoing Mechanical Reperfusion Clinical Trial
Official title:
International Study on Acute Coronary Syndromes - ST-segment Elevation Myocardial Infarction COVID 19
The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
This is a retrospective multicenter registry including at least 40 European primary PCI
centers with > 120 primary PCI/year (with expected average > 10/month), with the case load of
STEMI not expected to be affected by a potential planned reorganization of the STEMI network.
The inclusion period will be of 2 months (from March 1st until April 30th). The data will be
compared with those retrospectively collected in the same time window of 2019.
Inclusion criteria: STEMI treated by primary angioplasty. Primary study outcome: Number of
STEMI patients undergoing primary angioplasty. Secondary study outcomes: Ischemia time and
the number of late presenters (> 12 hours from symptoms onset); 3) Door-to-balloon time and
the number of patients with a DTB > 30 minutes); 4) In-Hospital mortality.
Data Collection: Data will be collected anonymized through a dedicated CRF. Each center will
identify a local Principal Investigator. We will collect information on the study center,
demographic, clinical, procedural data. Furthermore, we will collect data on total ischemia
time, door-to-balloon time, type of access to the emergency system, COVID positivity, PCI
procedure, data on in-hospital mortality.
;